Evidence map›Paper›PMID 38405181›Full record

ArticleParasite epidemiology and control2024

Impact of repeated mass ivermectin administration using a community directed approach on

Glory N Amambo, Fanny F Fombad, Patrick W Chounna Ndongmo, Raphael Awah Abong, Abdel Jelil Njouendou, Amuam Andrew Beng, Theobald Mue Nji, Mathias Eyong Esum, Jerome Fru-Cho, Ritter Manuel and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasite epidemiology and control, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 6 countries.

Glory N AmamboParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Fanny F FombadParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Patrick W Chounna NdongmoParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Raphael Awah AbongParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Abdel Jelil NjouendouParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Amuam Andrew BengParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Theobald Mue NjiRes1earch Foundation for Tropical Diseases and Environment (REFOTDE), P.O. Box 474, Buea, Cameroon.
Mathias Eyong EsumParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Jerome Fru-ChoParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Ritter ManuelInstitute of Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany.
Deribe KebedeGlobal Health and Infection Department, Brighton and Sussex Medical School, Brighton BN1 9PX, United Kingdom.
Peter Ivo EnyongParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
Achim HoeraufInstitute of Medical Microbiology, Immunology, and Parasitology, University Hospital Bonn, Germany.
Benjamin KoudouUnité de Formation et de Recherche Sciences de la Nature, Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
Moses BockarieCentre for Neglected Tropical Diseases (Incorporating the Lymphatic Filariasis Support Centre), Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Samuel WanjiParasites and Vector Research Unit (PAVRU), Department of Microbiology and Parasitology, University of Buea, P.O. Box 63, Buea, Cameroon.
University of Buea · CMLiverpool School of Tropical Medicine · GBUniversity Hospital Bonn · DEBrighton and Sussex Medical School · GBSwiss Centre for Scientific Research · CI

Funding

Wellcome Trust 201900/Z/16/Z
6 · The paper itself

Abstract

Background: Loiasis is an endemic filarial infection in the rainforest zone of West and Central Africa. Repeated annual community-directed treatment with ivermectin (CDTI) delivered for several years to control onchocerciasis has been shown to reduce the prevalence and intensity of Loiasis in some Methods: The study was conducted in the East, North-west and South-west 1 CDTI project sites of Cameroon. Two communities per CDTI project were selected for fly collection and dissection. Ivermectin treatment coverage was documented in these areas, and this was correlated to Results: Conclusion: This study demonstrated that the impact of repeated annual treatment with ivermectin for the control of onchocerciasis using community directed delivery approach on the entomological indicators of loiasis varies with bioecological zones. Community directed treatment with ivermectin induced a significant reduction in the entomological indicators of loiasis in the North-West project site which lies in forest savanna area. A non-significant decrease was observed in the East project site and in contrast, a significant increase was observed in the South-West 1 project site which both lies in the rainforest zones.

Indexed as

CDTIChrysopsIvermectinLoa loaMicroscopy

Identifiers

PMID38405181
PMCPMC10884510
OpenAlexW4391896078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.